anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: It remains unknown whether composite-dietary-antioxidant-index (CDAI) is associated with the risk of sarcopenia. This study investigated the association of CDAI with sarcopenia risk among general US adults.
METHODS: A total of 10,093 participants were enrolled in the National Health and Nutrition Examination Surveys (NHANES) from 6 survey cycles (2003-2004, 2005-2006, 2011-2012, 2013-2014, 2015-2016 and 2017-2018). Multivariate logistic regression was carried out to examine the relationship between CDAI and the risk of sarcopenia. Restricted cubic spline (RCS) curves were employed to analyze nonlinear relationships.
RESULTS: In a multi-variable logistic regression model adjusting for demographics, lifestyle, economic status and other dietary factors, higher CDAI score was related to a lower risk of sarcopenia among US adults. Compared the highest quartile of CDAI score with the lowest, the OR and 95%CI were 0.49 (0.31-0.75). Furthermore, the RCS demonstrated a linear dose-response relationship between CDAI and sarcopenia (P non-linearity=0.92). These results remained consistent across subgroups stratified by age, sex, physical activity, drinking status, body mass index (BMI), smoking habits, energy intake, and Healthy Eating Index (HEI) score. In addition, the favorable associations of CDAI were primarily attributed to Vitamin E intake.
CONCLUSION: A higher CDAI score was associated with a lower risk of sarcopenia. According to these results, a greater adherence to CDAI may benefit sarcopenia prevention in adults.
The blood clam (Tegillarca granosa), a marine bivalve of ecological and economic significance, often encounters intermittent hypoxia in mudflats and aquatic environments. To study the response of blood clam foot to prolonged intermittent hypoxia, the clams were exposed to intermittent hypoxia conditions (0.5 mg/L dissolved oxygen, with a 12-h interval) for 31 days. Initially, transcriptomic analysis was performed, uncovering a total of 698 differentially expressed genes (DEGs), with 236 upregulated and 462 downregulated. These genes show enrichments in signaling pathways related to glucose metabolism, sugar synthesis and responses to oxidative stress. Furthermore, the activity of the enzyme glutathione peroxidase (GPx) and the levels of gpx1 mRNA showed gradual increases, reaching their peak on the 13th day of intermittent hypoxia exposure. This observation suggests an indirect protective role of GPx against oxidative stress. The results of this study make a significantly contribute to our broader comprehensive of the physiological, biochemical responses, and molecular reactions governing the organization of foot muscle tissue in marine bivalves exposed to prolonged intermittent hypoxic conditions.
Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for resource tracking and allocation are disclosed. In one aspect, a method includes the actions of receiving data that reflects characteristics of a user. The actions further include receiving data that reflects first medical resources that are available at a first healthcare facility. The actions further include receiving data that reflects second medical resources that are available at a second healthcare facility. The actions further include, based on the user data and medical resource data, determining whether to generate and output a recommendation for the user to visit the first or second healthcare facility. The actions further include, based on the user data and medical resource data, predicting the needs of the first and second healthcare facilities and generating and outputting recommendations to allocate medical resources according to those needs.
Hydroxyphenyltriazines of formula <FORM:1033387/C4-C5/1> where X is hydrogen or methyl are used as U.V. protecting agents in soaps.ALSO:Hides, skins and leather may be protected against heat, air or ultra-violet light by means of hydroxphenyltriazines of formula <FORM:1033387/C6-C7/1> where X is hydrogen or methyl.ALSO:The invention comprises compounds of formula <FORM:1033387/C2/1> where X is hydrogen or methyl.  They may be prepared by Friedel-Crafts condensation of a compound of formula <FORM:1033387/C2/2> with resorcinol, to give a compound of formula <FORM:1033387/C2/3> and etherifying the para hydroxy group in known manner. Alternatively the above monochloro-1,3,5-triazines may be condensed with a 1,3-dialkoxy benzene of formula <FORM:1033387/C2/4> in a Friedel-Crafts reaction, the ortho-alkoxy group (Z1) being split in the reaction.  The products are used to protect organic materials of many types against heat, air and, particularly, ultra-violet irradiation.  The compound of formula <FORM:1033387/C2/5> is prepared as an intermediate in the first of the above processes.ALSO:Hydroxyphenyltriazines of formula <FORM:1033387/C3/1> where X is hydrogen or methyl may be used as heat, air or U.V. protecting agents for polymeric materials including:  epoxy resins, polyester resins, vinyl resins, polystyrene resins, alkyd resins, aldehyde resins such as phenol-, urea- or melamine-formaldehyde resins, emulsions of synthetic resins, rubber, latex, balata, gutta-percha, polychloroprene, olefinic polysulphides, polybutadiene, butadiene-styrene or butadiene-acrylonitrile copolymers; lacquers and films based on cellulose esters, vinyl acetate, polyvinyl chloride, polyvinylidene chloride, copolymers from vinyl chloride and vinylidene chloride, alkyd lacquers, polyethylene, polypropylene, polyamides, polyacrylonitrile and polyesters; polyamide and polyacrylonitrile spinning masses.  The triazines may be added before, during or after polymerization.ALSO:Cosmetic preparations such as perfumes, bath salts, skin and face creams, powder, repellants and sun-protection oils and creams contain as U.V. protection agents hydroxyphenyltriazines of formula <FORM:1033387/A5-A6/1> where X is hydrogen or methyl.ALSO:Hydroxyphenyltriazines of formula <FORM:1033387/B1-B2/1> where X is hydrogen or methyl may be used as heat, air of U. V. protecting agents in coatings for textiles and paper, for instance those based on starch or caslin or on plastics derived from, for example, vinyl acetate or acrylic acid derivatives.ALSO:Hydroxyphenyltriazines of formula <FORM:1033387/D1-D2/1> where X is hydrogen or methyl are used to protect organic materials from U.V., heat or air.  Materials protected include: textile fibres, threads, yarn, woven or knitted goods or felt derived from wool, silk, cotton, hemp, flax, linen, jute, ramie, regenerated cellulose, polyacrylonitrile, polyvinylchloride, polyolefines, polyesters or polyamides; feathers, hair, straw, wood, wood pulp, paper, cardboard, hardboard and Hollander pulp. In Example 8, a polyamide fibre is placed in an aqueous-alcoholic dispersion of one of the triazines which is then heated to boiling and the fabric rinsed and dried.
Cerebral stroke is ranked as the third most common contributor to global mortality and disability. The involvement of inflammatory mechanisms, both peripherally and within the CNS, holds significance in the pathophysiological cascades following the initiation of stroke. After the onset of acute stroke, predominantly ischemic, a subsequent phase of neuroinflammation ensues. It is a dual-effect process that not only exacerbates injury, leading to cell death, but paradoxically, it also serves a shielding role in facilitating recovery. Cytokines serve as pivotal mediators within the inflammatory cascade, actively contributing to the progression of ischemic damage. Stroke is followed by increased expression of pro-inflammatory cytokines including TNF-α, IL-1β, IL-6, etc. leading to the recruitment and stimulation of glial cells and peripheral leukocytes at the site of injury, promoting neuroinflammation. Cytokines can directly induce neuronal injury and death through various mechanisms, including excitotoxicity, oxidative stress, HPA-axis activation, secretion of matrix metalloproteinase and apoptosis. They can also amplify the inflammatory response, leading to further neuronal damage. Therapeutic strategies aimed at modulating cytokine release, immune response and cytokine signalling or activity are being explored as potential interventions to mitigate neuroinflammation and its detrimental effects in stroke. In this review, we have given a concise summary of our current knowledge of the function of various cytokines, brain inflammation and various signalling and molecular pathways including JAK/STAT3, TGF-β/Smad, MAPK, HMGB1/TLR and NF-κB modulated cytokines regulation in stroke. Therapeutic agents such as MCC950, genistein, edaravone, minocycline, etc. targeting various cytokines-associated signalling pathways have shown efficacy in preclinical and clinical trials reducing the pathophysiology of the illness were also addressed in this study.
The dose will be 0.1 mg / kg (= 10 mg/kg) and diluted in a 100 mL infusion bag of sodium chloride. The product will have to be administered as a slow infusion over 10 minutes.
The theranostic biocompatible microcapsules provided are efficient contrast enhanced imaging agents that combine Magnetic Resonance Imaging (MRI) with ultrasound-triggered drug release for real-time tracking and targeted delivery in vivo. The capsules are assembled via layer-by-layer deposition of the natural polyphenol tannic acid and poly(N-vinylpyrrolidone) with iron oxide nanoparticles incorporated in the capsule wall. The nanoparticle-modified capsules exhibit enhanced T 1  and T 2  MRI contrast in a clinical MRI scanner. Loaded with the an anticancer drug such as doxorubicin the capsules circulate in the blood stream for at least 48 hours, an improvement compared to non-encapsulated nanoparticles. High-intensity focused ultrasound results in targeted drug release with a 16-fold increase in the pharmacologically active agent localization in tumors compared to off-target organs. Owing to the active contrast, long circulation, customizable size, shape, composition, and precise delivery of high payload concentrations, these materials present an improved platform for imaging-guided precision drug delivery.
A comparatively thick sheet of a spongy hydrogel, made, e.g., by polymerizing ethylene glycol monomethacrylate in presence of less than 2 percent of a cross-linking agent and more than 60 percent of water, is laminated with a much thinner sheet of the same or similar, but homogeneous hydrogel, either from one side or from both sides. Alternatively, one external layer may be less hydrophilic or fully hydrophobic. The lamination is carried out so that the external thin layer is made on a glass or other smooth pad, either by polymerizing a cross-linked or linear polymer thereon, or by casting a thin layer of a dissolved linear polymer. Then a monomer mixture for spongy hydrogel is cast onto the first layer and polymerized. A sandwich structure is obtained if the monomer mixture for spongy hydrogel is cast between two pads provided with a thin homogeneous polymer layer. Hydrogel laminates and sandwich structures are useful, e.g., for surgical and cosmetic purposes, for filtering liquids, etc.
The subject will begin receiving the PEGASYS at a dose level of 45 micrograms weekly and gradually get increased to the maximum dose of 180 micrograms per week. The dose will be administered by prefilled syringes that will be injected subcutaneously. Subjects will receive therapy for up to 12 months.
OBJECTIVE: To review the role of sacro-iliac magnetic resonance imaging (MRI) in the diagnosis of axial spondyloarthritis (AxSpA), with a focus on gender differences.
METHODS: The experience of the authors and the results of an informal literature review are reported.
RESULTS: Inflammatory changes of the sacro-iliac joint are the hallmark of AxSpA. Early, non-radiographic sacroiliitis may be diagnosed with MRI through the assessment of bone marrow edema (BMO) as well as concomitant structural damage. The MRI protocol should include three necessary sequences, i.e., fat-saturated T2-weighted sequences on two orthogonal planes, T1-weighted semi-coronal sequence, and fat-suppressed T1-weighted semi-coronal sequence. Inflammatory changes comprise required signs (BMO and/or osteitis) and additional signs, including synovitis (better defined as joint space enhancement), enthesitis, and capsulitis. Structural changes consist of erosions, sclerosis, fat metaplasia, and ankylosis. Due to mechanical axial strain, inflammatory changes in the sacro-iliac joint can be found in healthy individuals, runners, and patients with nonspecific low back pain. The prevalence of BMO is higher in women during pregnancy and postpartum, even 12 months after childbirth, but the extent and distribution of MRI findings may help in the differential diagnosis. Other challenges in the MRI diagnosis of sacroiliitis are subchondral T2 hyperintensity during developmental age, periarticular sclerosis in healthy subjects, or osteitis condensans ilii, and several pathological conditions that may mimic AxSpA, some of which are more frequently found in women.
CONCLUSIONS: The described diagnostic challenges impose a multidisciplinary approach combining imaging findings with clinical and laboratory data.
NEW MATERIAL:A neurotropic peptide having physicochemical and biological properties and an amino sequence expressed by the formula (X is masked Ala, etc.) with mol.wt.: 700-1400 (by gel filtration method), contained in a water-soluble fraction of caverrous tissue as a pure peptide form. This neurotropic peptide stimulates the acetylcholine-synthetic activity of cholinergic neurons. USE:A therapeutic agent for Arzheimer geriatric dementia, parachordal sclerotic symptom with muscular atrophy, Parkinson's disease, etc. PREPARATION:For example, a rat carvenous tissue is homogenized, centrifuged and glacial acetic acid is added to the supernatant. The resultant precipitate is eliminated by the centrifugation and the supernatant is ultrafiltered. The filtrate is lyophilized, re-dissobuted to a buffer and purified by a reverse phase chromatography to obtain the objective neurotropic peptide.
Chronic obstructive pulmonary disease (COPD) is a prevalent lung condition characterized by airflow obstruction, disability, and high mortality rates. Magnolol (MA), known for its anti-inflammatory and antioxidant properties, holds the potential for alleviating COPD symptoms. However, MA faces challenges like poor aqueous solubility and low bioavailability. Herein MA-loaded nanostructured lipid carriers (MA-NLC) were prepared using emulsification and solvent evaporation. These carriers exhibited a particle size of (19.67 ± 0.36) nm, a polydispersity index of (0.21 ± 0.01), and a zeta potential of (-5.18 ± 0.69) mV. The fine particle fraction of MA-NLC was (68.90 ± 0.07)%, indicating minimal lung irritation and enhanced safety. Pulmonary delivery of MA-NLC via nebulizer actively targeted the diseased lung tissues, facilitated slow release, and overcame the challenges of low oral absorption and bioavailability associated with MA. This formulation prolonged the residence time of MA and optimized its therapeutic effect in pulmonary tissues. Upon pulmonary administration, MA-NLC effectively regulated inflammatory and oxidative stress markers in COPD models, demonstrating its potential as a promising therapeutic platform for COPD management.
OBJECTIVE: Systemic inflammation following traumatic brain injury (TBI) has been extensively studied over the past decades, as it contributes significantly to the pathophysiological injury mechanisms and subsequent poor outcomes. Systemic immune-inflammation (SII) index is a novel biomarker of systemic inflammatory response. However, its predictive value regarding TBI prognosis in clinical practice remains insufficiently investigated.
METHODS: A total of 102 TBI patients admitted to Nanjing Drum Tower Hospital from July 2019 to February 2022 were enrolled. We employed various statistical analyses to evaluate the correlation between inflammatory indicators upon admission and patient prognosis, compared the predictive accuracy of these indicators, and generated receiver operating curve analysis to test their prognostic performance.
RESULTS: The SII index, platelet count, absolute lymphocyte count, and neutrophil/lymphocyte ratio (NLR) were capable of distinguishing TBI prognosis according to univariate logistic regression models (P < 0.05). Multivariate logistic regression models revealed that increased SII index, platelet count, and NLR upon admission were independent predictors of poor TBI prognosis (P < 0.05). Receiver operating curve analysis further demonstrated that the SII index (area under the curve = 0.845, 95% confidence interval 0.769-0.921, P = 0.000) exhibited higher predictive ability than the NLR (area under the curve = 0.694, 95% confidence interval 0.591-0.796, P = 0.001).
CONCLUSIONS: Our findings suggested that increased SII index during the early stages of TBI was an independent risk factor for poor prognosis with satisfactory predictive value. The SII index provides a reliable, convenient, and cost-effective prognostic model to evaluate systemic inflammation after TBI and identify patients at risk of poor outcomes, thereby offering valuable guidance for clinical practice.
The patients are administered with sedation of midazolam analgesia of remifentanil on the basis of routine treatment. If the patient does not receive sedative drugs before enrollment, patients would be administered with a bolus of midazolam with 0.01-0.05mg/kg intravenously in 1 minute for the first time. And the maintenance dose is 0.02-0.1mg/kg/h, meanwhile the dose of midazolam should be titrated according to RASS scores. Nonbenzodiazepines could be administrated to the patients if sedation targets were not achieved, and the medication and dosage is recorded.
It has been reported that the frequency of adverse drug reactions to IGIV increases with the infusion rate. Initial infusion rates should be slow. If there are no adverse drug reactions, the infusion rate for subsequent infusions can be slowly increased to the maximum rate. For patients experiencing adverse drug reactions, it is advisable to reduce the infusion rate in subsequent infusions.

Table 1: Recommended Infusion Rates for BIVIGAM 

Monitor patient vital signs throughout the infusion. Slow or stop the infusion if adverse reactions occur. If symptoms subside promptly, the infusion may be resumed at a lower rate that is comfortable for the patient.

Ensure that patients with pre-existing renal insufficiency are not volume depleted. For patients judged to be at risk for renal dysfunction or thrombotic events, administer BIVIGAM at the minimum infusion rate practicable, and consider discontinuation of administration if renal function deteriorates ( see Boxed Warning, Warnings and Precautions [5.1, 5.3]).
NEW MATERIAL: An L-carnitine magnesium citrate represented by the formula. USE: A composite formulation or a pharmacological agent of carnitine and magnesium, having low hygroscopicity, good in thermal stability and useful in sports nutritions. PREPARATION: A magnesium compound, e.g. Mg(OH)2 , MgO or MgCl2 , preferably Mg(OH)2 , citric acid and L-carnitine in repective equiv. amounts or magnesium citrate and L-carnitine in respective equiv. amounts are respectively reacted in a solvent to afford the compound represented by the formula. The compound is capable of manifesting excellent efficacies in higher performances and improved endurance in sports as well as shorter rest periods, rapid resilience, balancing of the increased magnesium and L-carnitine demand in competitive sports, delay of fatigue, strengthening of cardiac muscle, prevention of cardiac irregularities, improvement in stress tolerance, prevention of muscle and vascular spasms, improvement in muscular activities and improvement in activities of enzymic reactions in energy metabolism.
Newborn babies who are 28 days old or less with a corrected gestational age of at least 34 weeks and a weight of at least 1700g or more at the time of participation. They will be recruited from hospital neonatal units or wards.
Preparation method and application of astaxanthin H1-, or H2- or J-aggregate water dispersion system are provided. The three kind of color-different astaxanthin multimer nano-dispersion systems utilize a special molecular structure of natural biomacromolecule chitosan and fish sperm DNA as well as physical interaction between macromolecules to induce formation and stability of astaxanthin multimers under solvent and salt ion-effects. Low-toxicity ethanol is selected as a good solvent for astaxanthin. The organic solvent can be completely removed in the later stage of the preparation process, and can be further enriched and recycled, which is beneficial to clean production and low cost. By adjusting process parameters, the H1-, or H2- or J-type astaxanthin aggregate water dispersion system can be obtained, so as to control a coloration range of astaxanthin water-based products to be yellow, orange and pink. Furthermore, during concentration, dehydration and reconstitution, astaxanthin aggregation patterns and coloring effects are maintained.
PURPOSE:To obtain an immunosuppressive agent having strong action effects and slight side effects, comprising a prostaglandin-containing fat emulsion having excellently immunosuppressive action as a main component. CONSTITUTION:A prostaglandin-containing fat emulsion such as fat emulsion of purified soybean oil containing PGA, PGA2, PGB1, PGD2, PGE, PGE2, PGF1alpha, PQF2alpha, PGI2 or its derivatives (especially preferably PGE1) is used as a main compound. This fat emulsion consists of 100 pts.wt. vegetable oil such as soybean oil, 1-50 pts.wt., preferably 5-30 pts.wt. phospholipid and a proper amount of water. This PG-containing fat emulsion is a component effective as an immunosuppressive agent in treatment for suppressing rejection (immune) reaction especially during transplanting of organs. Since this immunosuppressive agent is of a fat emulsion form having excellent sustained release and local (lesion) concentration besides excellent immunosuppressive action, the immunosuppressive agent has strong action effects and can improve take ratio of transplanted organs with a low dose. Since PG itself is a physiologically active substance, it has low side effects. The immunosuppressive agent is extremely useful clinically.
BACKGROUND: Hydrops fetalis (HF) is fluid accumulation in fetus body cavities and subcutaneous tissue. The condition has been described in various farm and companion animal species, including dogs. Most of cases result from a heart defect. Exact nature of this defect is rarely clarified.
CASE PRESENTATION: A newborn, male French bulldog puppy with severe HF underwent a full anatomopathological examination to diagnose the primary cause of HF. Based on the anatomopathological examination, fetal ultrasound, and micro-computed tomography, transposition of the great arteries with hypoplasia of the ascending aorta, aortic arch interruption, ostium secundum atrial septal defect, severe tricuspid valve dysplasia, as well as hypoplasia of pulmonary vessels and lungs were diagnosed.
CONCLUSIONS: This is the first report of HF caused by severe, complex congenital heart defects with concurrent pulmonary vessel and lung hypoplasia.